API | endoxifen

endoxifen Report issue

Small molecule Experimental

AACT PubChem

Active Ingredient History

NOW

Endoxifen, also known as 4-hydroxy-N-desmethyltamoxifen, is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group as well as a protein kinase C (PKC) inhibitor. It is under development for the treatment of estrogen receptor-positive breast cancer and for the treatment of mania in bipolar disorder. It is taken by mouth. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
- Estrogen receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

endoxifen hydrochloride | z-endoxifen

Organizations (14)

Research & Development (14)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (7)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (7)

Bipolar Disorder (Phase 3)

Breast Density (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma, Intraductal, Noninfiltrating (Phase 2)

Female Urogenital Diseases (Phase 1)

Fibromatosis, Aggressive (Phase 1)

Neoplasms (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 10
# of Trial Organizations: 14

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue